Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
23 Results for "
SS cells
" in MedChemExpress (MCE) Product Catalog:
Products (23)
23 Results for "SS cells" in MCE Product Catalog:
7
7 Cited Publications
Art. -Nr.: HY-148739
CAS. Nr.: 2170679-42-0
Target:
Forschungsgebiete:
dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma .
Art. -Nr.: HY-178042
CAS. Nr.: 2756257-56-2
SS-3091 is a pan-KRas inhibitor active across KRas G12D, KRas G12C, KRas G12V, KRas G12S mutants, with minimal effects on non-KRas-driven cancer cells. SS-3091 binds to the KRas·ARaf interaction interface, destabilizes the complex, and attenuates KRas activity. SS-3091 suppresses phosphorylation of S6K, Akt, and ERK. SS-3091 reduces proliferation and decreases colony formation of cancer cells bearing KRas G12 mutations. SS-3091 can be used for the research of KRas-driven cancers .
Art. -Nr.: HY-P99506
CAS. Nr.: 2148325-59-9
Synonyms: SC-003 mAb; SC-Mab003; SC34.28SS1
Target:
Forschungsgebiete:
Art. -Nr.: HY-146231
CAS. Nr.: 2636072-62-1
Forschungsgebiete:
SS47 is a hematopoietic progenitor kinase HPK1 PROTAC-class degrader and immune activator. SS47 promotes the proliferation of CD4+ and CD8+ T cells as well as IFN-γ secretion, and enhances the anti-tumor cytotoxicity and in vivo efficacy of BCMA CAR-T cells. SS47 also inhibits tumor growth in mouse models, and when combined with anti-PD-1 therapy, it improves the immune response of 4T1 tumor-bearing mice. SS47 can be used in breast cancer-related research .
Art. -Nr.: HY-146231A
Reinheit: 99.88%
Forschungsgebiete:
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Art. -Nr.: HY-D1254
CAS. Nr.: 2368978-96-3
Synonyms: NBL-SS perchlorate
Art. -Nr.: HY-W105741
CAS. Nr.: 73367-80-3
Target:
Forschungsgebiete:
12-Bromododecanoic acid is a bromo fatty acid. 12-Bromododecanoic acid can be used in the synthesis of clickable forms of myristic acid. 12-Bromododecanoic acid inhibits HIV replication in CEM-SS T cells (EC50 = 38 µM) .
Art. -Nr.: HY-144793
Target:
Forschungsgebiete:
Deac-SS-Biotin is a potent antitumor agent with improved tumor targeting effects and reduced off-target toxicities. Deac-SS-Biotin uptakes into the cells through biotin-mediated internalization. Deac-SS-Biotin combined with DTT (Glutathione mimetic) can effectively inhibit microtubule assembly and displays greater antitumor activity .
Art. -Nr.: HY-100761
CAS. Nr.: 141172-08-9
Target:
Forschungsgebiete:
SS28, a SRT501 analog with oral bioavailability, inhibits tubulin polymerization to cause cell cycle arrest at G2/M phase. SS28 results in apoptosis rather than necrosis tubulin .
Art. -Nr.: HY-155745
CAS. Nr.: 2759277-20-6
Antitumor agent-115 (SS-12) is an effective anti-tumor compound with an IC50 value of 0.34 μM-24.14 μM for cell line 4T1. Antitumor agent-115 can block the cell cycle of mouse breast cancer cell line 4T1, reduce the mitochondrial membrane potential, and induce apoptosis, and the IC50 value is 8-25 μmol/L for cell viability. Antitumor agent-115 can be used for breast cancer research .
Art. -Nr.: HY-P5738
CAS. Nr.: 331714-57-9
Art. -Nr.: HY-N14144
CAS. Nr.: 182285-29-6
Category:
Target:
Art. -Nr.: HY-174250
Target:
Forschungsgebiete:
PTP1B-IN-31 (Compound (S,S)-3ak) is a PTP1B inhibitor with an IC50 of 0.81 μM. PTP1B-IN-31 can inhibit the growth of tumor cells in synergy with the cytokine IFNγ. PTP1B-IN-31 can be used in cancer research .
Art. -Nr.: HY-181017
Forschungsgebiete:
Ola-NC-SS-PEG-Lap is a selective immunogenic cell death inducer. Ola-NC-SS-PEG-Lap exploits the synergistic interplay between an NQO1-bioactivated compound and a PARP inhibitor to selectively induce immunogenic cell death in tumor cells without harming normal cells. Ola-NC-SS-PEG-Lap induces ROS accumulation, increases DNA damage. Ola-NC-SS-PEG-Lap can be activated by GSH and release Ola, ultimately producing the synergistic antitumor effect with the Lap portion. Ola-NC-SS-PEG-Lap has anti-cancer activity against colon cancer .
Art. -Nr.: HY-D2930
Synonyms: SNAP-SS-SulfoCy5
Art. -Nr.: HY-N14530
CAS. Nr.: 11050-22-9
Category:
Target:
Art. -Nr.: HY-W305227
CAS. Nr.: 923255-75-8
Target:
Forschungsgebiete:
INN-312 is a sickle hemoglobin (Hb S) inhibitor capable of penetrating red blood cell membranes. INN-312 inhibits sickling of sickle red blood cells under hypoxic conditions, increases the oxygen affinity of Hb, and moderately improves the solubility of deoxygenated Hb S. INN-312 can be used in research related to sickle cell disease .
Art. -Nr.: HY-165513
CAS. Nr.: 173268-90-1
Niruriside is a HIV REV/RRE complex inhibitor. Niruriside specifically inhibits the binding interaction between HIV REV protein and RRE RNA, with an IC50 of 3.3 μM, and shows no significant activity against the unrelated R17 capsid protein/operator RNA binding system. At the tested concentrations, Niruriside fails to protect CEM-SS cells from acute HIV-1 infection. Niruriside can be used in the research of human immunodeficiency virus (HIV) infection .
Art. -Nr.: HY-180566
CAS. Nr.: 3049284-11-6
HIV-IN-13 (compound 7) is a potent HIV inhibitor with low cellular toxicity. HIV-IN-13 inhibits HIV in CEM-SS cells with an EC50 of 1.38 μM. HIV-IN-13 displays antiviral activity in hPBMCs infected with different HIV strains (EC50 = 2.01-10.7 μM), while showing low cellular toxicity (TC50 >100 μM). HIV-IN-13 can be used for HIV-infection research .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
